Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (macaca mulatta)

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7283-7291

  Saunders, David ^a   Vanachayangkul, Pattaraporn ^a   Imerbsin, Rawiwan ^a   Khemawoot, Phisit ^a   Siripokasupkul, Raveewan ^a   Tekwani, Babu L ^b,c   Sampath, Aruna ^b   Nanayakkara, N P Dhammika ^b   Ohrt, Colin ^d   Lanteri, Charlotte ^a   Gettyacamin, Montip ^a   Teja Isavadharm, Paktiya ^a   Walkerc, Larry ^b,c  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; METHEMOGLOBIN; PRIMAQUINE; ANTIMALARIAL AGENT;

AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ENANTIOMER; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OXIDATIVE STRESS; PARASITE CLEARANCE; PARASITEMIA; PHARMACODYNAMICS; PLASMODIUM CYNOMOLGI; RHESUS MONKEY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANIMAL; BLOOD; CHEMISTRY; DISEASE MODEL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; KIDNEY; LIVER; MALARIA; MALE; METABOLISM; PARASITOLOGY; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; RECURRENT DISEASE; STEREOISOMERISM;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY; LIVER; MACACA MULATTA; MALARIA; MALARIA, VIVAX; MALE; METHEMOGLOBIN; OXIDATIVE STRESS; PLASMODIUM CYNOMOLGI; PLASMODIUM VIVAX; PRIMAQUINE; RECURRENCE; STEREOISOMERISM;

EID: 84912120444     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02576-13     Document Type: Article

References (32)

1. Brewer GJ, Tarlov AR, Kellermeyer RW, Alving AS. 1962. The hemolytic effect of primaquine. XV. Role of methemoglobin. J. Lab. Clin. Med. 59: 905-917.
2. Myint HY, Berman J, Walker L, Pybus B, Melendez V, Baird JK, Ohrt C. 2011. Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations. Am. J. Trop. Med. Hyg. 85:1010-1014. http://dx.doi.org /10.4269/ajtmh.2011.11-0498.
3. Beutler E. 1959. The hemolytic effect of primaquine and related compounds: a review. Blood 14:103-139.
4. Vale N, Moreira R, Gomes P. 2009. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44:937-953. http://dx.doi.org/10.1016/j .ejmech.2008.08.011.
5. Nanayakkara NP, Ager AL, Jr, Bartlett MS, Yardley V, Croft SL, Khan IA, McChesney JD, Walker LA. 2008. Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrob. Agents Chemother. 52:2130-2137. http://dx.doi .org/10.1128/AAC.00645-07.
6. Tekwani BL, Walker LA. 2006. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis. 19:623-631. http://dx.doi.org/10 .1097/QCO.0b013e328010b848.
7. Zhang C, Zhu C, Lin X, Gao F, Wei Y. 2002. Enantiomeric separation of primaquine, an anti-malarial drug, by cyclodextrin-modified micellar electrokinetic capillary chromatography. Anal. Sci. 18:595-597. http://dx .doi.org/10.2116/analsci.18.595.
8. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN. 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar. J. 11:280. http://dx.doi.org/10.1186/1475 -2875-11-280.
9. Baker JK, McChesney JD. 1988. Differential metabolism of the enantiomers of primaquine. J. Pharm. Sci. 77:380-382. http://dx.doi.org/10 .1002/jps.2600770503.
10. Nanayakkara NPD, Tekwani BL, Herath HMTB, Sahu R, Gettayamacin M, Tungtaeng A, van Gessel Y, Baresel P, Wickham K, Bartlett MS, Fronczek FR, Melendez V, Ohrt C, Reichard GA, McChesney JD, Rochford R, Walker LA. 2014. Primaquine enantiomers: scalable preparation and differential pharmacologic and toxicologic profiles. Antimicrob. Agents Chemother. 58:4737-4744. http://dx.doi.org/10.1128/AAC .02674-13.
11. Schmidt LH, Alexander S, Allen L, Rasco J. 1977. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob. Agents Chemother. 12:51-60. http://dx.doi.org/10 .1128/AAC.12.1.51.
12. Clyde DF. 1981. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull. World Health Organ. 59:391-395.
13. Solem E, Pirzer C, Siege M, Kollmann F, Romero-Saravia O, Bartsch-Trefs O, Kornhuber B. 1985. Mass screening for glucose-6-phosphate dehydrogenase deficiency: improved fluorescent spot test. Clin. Chim. Acta 152:135-142. http://dx.doi.org/10.1016/0009-8981(85)90184-6.
14. Deye GA, Gettayacamin M, Hansukjariya P, Im-erbsin R, Sattabongkot J, Rothstein Y, Macareo L, Fracisco S, Bennett K, Magill AJ, Ohrt C. 2012. Use of a rhesus Plasmodium cynomolgi model to screen for antihypnozoite activity of pharmaceutical substances. Am. J. Trop. Med. Hyg. 86:931-935. http://dx.doi.org/10.4269/ajtmh.2012.11-0552.
15. Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C. 2011. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar. J. 10:212. http://dx.doi.org/10.1186/1475-2875 -10-212.
16. Avula B, Khan SI, Tekwani BL, Nanayakkara NP, McChesney JD, Walker LA, Khan IA. 2011. Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. Biomed. Chromatogr. 25:1010-1017. http://dx.doi.org/10.1002/bmc.1557.
17. Nicholl DD, Edwards G, Ward SA, Orme ML, Breckenridge AM. 1987. The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. Biochem. Pharmacol. 36:3365-3369.
18. Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo Richie TL, Ohrt CK, Mouzin E, Church CJ, Richards AL, Wignall S, Mouzin E, Ohrt C, Subianto B, Sandjaja B, Hoffman SL. 1995. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 346: 1190-1193. http://dx.doi.org/10.1016 /S0140-6736(95)92898-7.
19. Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, Berman J. 1998. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebocontrolled trial. Ann. Intern. Med. 129:241-244.
20. Clark BB, Morrisey RW, Blair D. 1951. Relation of methemoglobin to hemolysis. Blood 6:532-543.
21. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL. 2012. Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology 294:54-60. http://dx.doi.org/10.1016/j.tox.2012.01.015.
22. Carmona-Fonseca J, Alvarez G, Maestre A. 2009. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am. J. Trop. Med. Hyg. 80:188-193.
23. Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, Gramzinski R, Sismadi P, Krisin Ling J, Wiady I, Kusumaningsih M, Jones TR, Fryauff DJ, Hoffman SL. 2001. Randomized, parallel placebocontrolled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin. Infect. Dis. 33:1990-1997. http://dx.doi.org/10.1086/324085.
24. Kantor GS. 1992. Primaquine-induced methemoglobinemia during treatment of Pneumocystis carinii pneumonia. N. Engl. J. Med. 327:1461. http://dx.doi.org/10.1056/NEJM199211123272016.
25. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM. 1984. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br. J. Clin. Pharmacol. 17: 441-446. http://dx.doi.org/10.1111/j.1365-2125.1984.tb02369.x.
26. Kristensen S, Nord K, Orsteen AL, Tonnesen HH. 1998. Photoreactivity of biologically active compounds, XIV: influence of oxygen on light induced reactions of primaquine. Pharmazie 53:98-103.
27. Agarwal S, Gupta UR, Daniel CS, Gupta RC, Anand N, Agarwal SS. 1991. Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine, primaquine enantiomers, and its two putative metabolites. II. Effect on red blood cell membrane, lipid peroxidation, MC-540 staining, and scanning electron microscopic studies. Biochem. Pharmacol. 41:17-21.
28. Brocks DR, Mehvar R. 2003. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin. Pharmacokinet. 42:1359-1382. http://dx.doi.org/10.2165/00003088-200342150 -00004.
29. Frischer H, Mellovitz RL, Ahmad T, Nora MV. 1991. The conversion of primaquine into primaquine-aldehyde, primaquine-alcohol, and carboxyprimaquine, a major plasma metabolite. J. Lab. Clin. Med. 117:468-476.
30. Constantino L, Paixao P, Moreira R, Portela MJ, Do Rosario VE, Iley J. 1999. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Exp. Toxicol. Pathol. 51:299-303.
31. Bowman ZS, Oatis JE, Jr, Whelan JL, Jollow DJ, McMillan DC. 2004. Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 309:79 - 85. http://dx.doi.org/10.1124/jpet.103 .062984.
32. Bhatia SC, Saraph YS, Revankar SN, Doshi KJ, Bharucha ED, Desai ND, Vaidya AB, Subrahmanyam D, Gupta KC, Satoskar RS. 1986. Pharmacokinetics of primaquine in patients with P. vivax malaria. Eur. J. Clin. Pharmacol. 31:205-210. http://dx.doi.org/10.1007/BF00606660.